ES2172482B1 - Adicion de la patente es200100402 "vacuna para la proteccion de perros frente a la leishmania". - Google Patents

Adicion de la patente es200100402 "vacuna para la proteccion de perros frente a la leishmania".

Info

Publication number
ES2172482B1
ES2172482B1 ES200102057A ES200102057A ES2172482B1 ES 2172482 B1 ES2172482 B1 ES 2172482B1 ES 200102057 A ES200102057 A ES 200102057A ES 200102057 A ES200102057 A ES 200102057A ES 2172482 B1 ES2172482 B1 ES 2172482B1
Authority
ES
Spain
Prior art keywords
vaccine
leishmania
addition
protection
against leishmania
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES200102057A
Other languages
English (en)
Other versions
ES2172482A1 (es
Inventor
Vicente E. Larraga Rodriguez De Vera
Gloria Gonzalez Aseguinolaza
M. Jesus Ramiro Ibañez
Juan Antonio Castillo Hernandez
Javier Lucientes Curdi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Consejo Superior de Investigaciones Cientificas CSIC
Laboratorios Hipra SA
Universidad de Zaragoza
Original Assignee
Consejo Superior de Investigaciones Cientificas CSIC
Laboratorios Hipra SA
Universidad de Zaragoza
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Superior de Investigaciones Cientificas CSIC, Laboratorios Hipra SA, Universidad de Zaragoza filed Critical Consejo Superior de Investigaciones Cientificas CSIC
Priority to US10/468,618 priority Critical patent/US8986711B2/en
Priority to PT02702414T priority patent/PT1371375E/pt
Priority to ES02702414T priority patent/ES2334493T3/es
Priority to AT02702414T priority patent/ATE439858T1/de
Priority to EP02702414A priority patent/EP1371375B1/en
Priority to DE60233391T priority patent/DE60233391D1/de
Priority to PCT/ES2002/000077 priority patent/WO2002066054A1/es
Publication of ES2172482A1 publication Critical patent/ES2172482A1/es
Application granted granted Critical
Publication of ES2172482B1 publication Critical patent/ES2172482B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/008—Leishmania antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Adición de la patente ES200100402 vacuna para la protección de perros frente a Leishmania. La presente adición se relaciona, en general, con la prevención de la Leishmaniasis en animales, en particular, con una vacuna para proteger animales, perros entre otros, de la infección causada por Leishmania sp., que comprende la proteína P36 de Leishmania infantum, o un fragmento inmunogénico de la misma, o bien un sistema de expresión de dicha proteína o fragmento, opcionalmente junto con un compuesto que estimula la producción de una respuesta inmune celular de tipo Th1; así como varios protocolos de vacunación frente a Leishmania sp a partir del empleo de dicha vacuna.
ES200102057A 2001-02-21 2001-09-12 Adicion de la patente es200100402 "vacuna para la proteccion de perros frente a la leishmania". Expired - Fee Related ES2172482B1 (es)

Priority Applications (7)

Application Number Priority Date Filing Date Title
PT02702414T PT1371375E (pt) 2001-02-21 2002-02-21 Vacina para a protecção de animais contra a leishmaníase âmbito técnico
ES02702414T ES2334493T3 (es) 2001-02-21 2002-02-21 Vacuna para la proteccion de animales frente a leishmania.
AT02702414T ATE439858T1 (de) 2001-02-21 2002-02-21 Vakzine zum schutz von tieren gegen leishmania
EP02702414A EP1371375B1 (en) 2001-02-21 2002-02-21 Vaccine to protect animals against leishmania
US10/468,618 US8986711B2 (en) 2001-02-21 2002-02-21 Vaccine to protect animals against leishmania
DE60233391T DE60233391D1 (de) 2001-02-21 2002-02-21 Vakzine zum schutz von tieren gegen leishmania
PCT/ES2002/000077 WO2002066054A1 (es) 2001-02-21 2002-02-21 Vacuna para la protección de animales frente a leishmania

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200100402A ES2171360B1 (es) 2001-02-21 2001-02-21 Vacuna para la proteccion de animales frente a la leishmania.

Publications (2)

Publication Number Publication Date
ES2172482A1 ES2172482A1 (es) 2003-07-16
ES2172482B1 true ES2172482B1 (es) 2004-12-01

Family

ID=8496822

Family Applications (2)

Application Number Title Priority Date Filing Date
ES200100402A Expired - Fee Related ES2171360B1 (es) 2001-02-21 2001-02-21 Vacuna para la proteccion de animales frente a la leishmania.
ES200102057A Expired - Fee Related ES2172482B1 (es) 2001-02-21 2001-09-12 Adicion de la patente es200100402 "vacuna para la proteccion de perros frente a la leishmania".

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES200100402A Expired - Fee Related ES2171360B1 (es) 2001-02-21 2001-02-21 Vacuna para la proteccion de animales frente a la leishmania.

Country Status (2)

Country Link
US (1) US8986711B2 (es)
ES (2) ES2171360B1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2313807B1 (es) * 2005-07-30 2009-12-23 Consejo Superior De Investigaciones Cientificas Vectores recombinantes basados en el virus vaccinia modificado de ankara (mva) como vacunas contra la leishmaniasis.

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GONZÁLEZ ASEGUINOLAZA et al. "Molecular cloning, cell localization and binding affinity to DNA replication proteins of the p36/LACK protective antigen from Leishmania infantum". 1999. Eur. J. Biochem., Vol. 259, páginas 909-916. *
GURUNATHAN et al. "Vaccination with DNA encoding the immuno-dominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major". Octubre 1997. The Journal of Experimental Medicine. Vol. 186 (7), páginas 1137-1147. *
MATTNER et al. "Interleukin-12 is indispensable for protective immunity against Leishmania major". Noviembre 1997. Infect. Immun., Vol. 65 (11), páginas 4378-4383. *
RAJA GABAGLIA et al. "A single intramuscular injection with adenovirus expressing IL-12 protects BALB/c mice against Leishmania major infection, while treatement whit an IL-4 expressing vector increases disease susceptibility in B10.D2 mice". 1999. J. Immunol., Vol. 162, páginas 753-760. *

Also Published As

Publication number Publication date
ES2172482A1 (es) 2003-07-16
ES2171360B1 (es) 2003-12-16
US20040156866A1 (en) 2004-08-12
US8986711B2 (en) 2015-03-24
ES2171360A1 (es) 2002-09-01

Similar Documents

Publication Publication Date Title
CO5611162A2 (es) Metodos para prevenir enfermedades reproductivas en el ganado vacuno
WO2006068663A3 (en) Vaccine compositions for treating coronavirus infection
WO2005116270A3 (en) Influenza virus vaccine composition and method of use
AR049014A1 (es) Mimeticuerpos de glp-1 humanos , composiciones y usos
EA200301323A1 (ru) Однократная вакцинация mycoplasma hyopneumoniae
ATE461710T1 (de) Nipah-virus-impfstoffe
DE602004024542D1 (de) Untereinheit-impfstoff gegen das respiratorische synzytialvirus
UA94717C2 (ru) Модифицированный вирус гриппа, предназначенный для мониторинга и повышения эффективности вакцины
CU23608A3 (es) Vacuna para la tuberculosis ureasa deficiente con eficacia mejorada
PA8549801A1 (es) Vacuna de mycoplasma bovis y metodos para reducir la neumonia en animales
CY1112575T1 (el) Βελτιωμενα αδρανοποιημενα εμβολια fcv
ATE458496T1 (de) Hiv-vakzine und anwendungsverfahren
DE60115051D1 (de) Immunologische adjuvans verbindungen
MXPA03009763A (es) Vacuna contra el virus de la enfermedad de la fiebre aftosa.
CY1107784T1 (el) Πρωτεϊνη συντηξης g του ihnv για διεγερση του ανοσοποιητικου συστηματος
ES2172482B1 (es) Adicion de la patente es200100402 "vacuna para la proteccion de perros frente a la leishmania".
EA200301151A1 (ru) Вакцина против натуральной оспы
ATE495758T1 (de) Virulentes systemisches felines calicivirus
DE60239753D1 (de) Impfstoff gegen infektiöses lachsanämievirus
ATE378351T1 (de) Therapeutische impfzusammensetzung zur verhütung und behandlung von erkrankungen bei säugetieren
AR045416A1 (es) Coadyuvante de linfocitos humanos para vacunas
ATE515270T1 (de) Phep, eine aminosäurepermease von staphylococcus aureus
DE60233391D1 (de) Vakzine zum schutz von tieren gegen leishmania
CY1107374T1 (el) Εμβολιο ιχθυος εναντι της piscirickettsia salmonis
DE60238554D1 (de) Vakzine gegen infektionskrankheiten

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20020916

Kind code of ref document: A1

Effective date: 20020916

EC2A Search report published

Date of ref document: 20030716

Kind code of ref document: A1

FG2A Definitive protection

Ref document number: 2172482B1

Country of ref document: ES

FD2A Announcement of lapse in spain

Effective date: 20190613